Vivozon’s VVZ-149, a nonopioid analgesics, has completed the 2a phase of clinical trials in the US, according to its largest stakeholder Telcon on Sept. 7.
The drug development venture was established in 2008 and its painkiller candidate is currently under phase 2b of clinical trials in the country. In the US the company has finished preparation for the phase 2b.
Telcon and its subsidiary KPM Tech will further increase their stakes in Vivozon and seek to diversify into biopharmaceutical business.
By Hwang You-mee (firstname.lastname@example.org